Hence, it is worth inputting more endeavors onto further mechanistic evaluations to validate these recommended hypotheses, and hopefully, discussions herein would shed light on the application of AMPK activators, VEGF/PD-1 blockades, and FITs in the treatment of human ovarian cancer. This evidence concerns the gene VEGFA and ovarian carcinoma.